BiotechTube

XmAb23104

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sarcoma

Conditions

Sarcoma

Trial Timeline

Apr 6, 2023 → Jul 19, 2024

NCT ID
NCT05879185

About XmAb23104

XmAb23104 is a phase 2 stage product being developed by Xencor for Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05879185. Target conditions include Sarcoma.

What happened to similar drugs?

1 of 15 similar drugs in Sarcoma were approved

Approved (1) Terminated (1) Active (13)
🔄Abemaciclib + PlaceboEli LillyPhase 3
🔄cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
🔄Trabectedin + Doxorubicin + IfosfamideJohnson & JohnsonPhase 3
❌LV305 + G305MerckPhase 3
✅Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirMerckApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05879185Phase 2Terminated

Competing Products

20 competing products in Sarcoma

See all competitors
ProductCompanyStageHype Score
Tc99m-tilmanoceptNavidea BiopharmaceuticalsPhase 1
19
Azenosertib + GemcitabineZentalis PharmaceuticalsPhase 1/2
22
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 1/2
22
AbemaciclibEli LillyPhase 2
39
Abemaciclib + PlaceboEli LillyPhase 3
44
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acidChugai PharmaceuticalPhase 3
44
PLX3397 + sirolimusDaiichi SankyoPhase 1/2
24
exatecan mesylateDaiichi SankyoPhase 2
35
efatutazoneDaiichi SankyoPhase 2
35
soblidotinDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
LinsitinibAstellas PharmaPhase 2
35
Fluzoparib+ DalpiciclibSun PharmaceuticalPhase 2
31
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+VincristineSun PharmaceuticalPhase 2
42
irinotecan liposome (II) + temozolomide + fluzoparibSun PharmaceuticalPhase 2
42
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
EribulinEisaiPhase 2
39
Lenvatinib + Ifosfamide + Etoposide + LenvatinibEisaiPhase 2
35